Individuals with a germline CDKN2A PV have an increased lifetime risk of up to 70% for melanoma and up to 20% for pancreatic cancer, and are recommended to undergo skin and pancreatic cancer surveillance [1–5]. This evidence concerns the gene CDKN2A and familial pancreatic carcinoma.